Name: chemical inactivation of the e3 ubiquitin ligase cereblon by pomalidomide-based homo-protacs
Uploaded: 2019-05-15T14:00:00
Description: Watch this Scientific Journal Video about Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs at JoVE.com

This work was supported by the Deutsche Forschungsgemeinschaft (Emmy-Noether Program Kr-3886/2-1 and SFB-1074 to J.K.; FOR2372 to M.G.)

1. Preparation of PROTAC molecules
CAUTION: Please consult all relevant material safety data sheets (MSDS) before use. Several of the chemicals used in these syntheses are toxic and carcinogenic. Please use all appropriate safety practices and personal protective equipment.
<ol>
	<li>Preparation of tert-butyl N-(2,6-dioxo-3-piperidyl)carbamate (compound 1)
	<ol>
		<li>Add 1,1&#39;-carbonyldiimidazole (1.95 g, 12 mmol) and a catalytic amount of 4-(dimethylam...

<ol>
	<li>Ito, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+of+a+primary+target+of+thalidomide+teratogenicity.">Identification of a primary target of thalidomide teratogenicity.</a> Science. 327 (5971), 1345-1350 (2010).</li><li>Lopez-Girona, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cereblon+is+a+direct+protein+target+for+immunomodulatory+and+antiproliferative+activities+of+lenalidomide+and+pomalidomide.">Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.</a> Leukemia. 26 (11), 2326-2335 (2012).</li><li>Fischer, E. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structure+of+the+DDB1-CRBN+E3+ubiquitin+ligase+in+complex+with+thalidomide.">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.</a> Nature. 512 (7512), 49-53 (2014).</li><li>Gandhi, A. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunomodulatory+agents+lenalidomide+and+pomalidomide+co-stimulate+T+cells+by+inducing+degradation+of+T+cell+repressors+Ikaros+and+Aiolos+via+modulation+of+the+E3+ubiquitin+ligase+complex+CRL4(CRBN).">Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN).</a> British Journal of Haematology. 164 (6), 811-821 (2014).</li><li>Kronke, J., Hurst, S. N., Ebert, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lenalidomide+induces+degradation+of+IKZF1+and+IKZF3.">Lenalidomide induces degradation of IKZF1 and IKZF3.</a> Oncoimmunology. 3 (7), e941742 (2014).</li><li>Lu, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+Ikaros+proteins.">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.</a> Science. 343 (6168), 305-309 (2014).</li><li>Zhu, Y. X., Kortuem, K. M., Stewart, A. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+mechanism+of+action+of+immune-modulatory+drugs+thalidomide,+lenalidomide+and+pomalidomide+in+multiple+myeloma.">Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.</a> Leukemia &amp; Lymphona. 54 (4), 683-687 (2013).</li><li>Chamberlain, P. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structure+of+the+human+Cereblon-DDB1-lenalidomide+complex+reveals+basis+for+responsiveness+to+thalidomide+analogs.">Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.</a> Nature Structural &amp; Molecular Biology. 21 (9), 803-809 (2014).</li><li>Donovan, K. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Thalidomide+promotes+degradation+of+SALL4,+a+transcription+factor+implicated+in+Duane+Radial+Ray+syndrome.">Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.</a> eLife. 7, (2018).</li><li>Matyskiela, M. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SALL4+mediates+teratogenicity+as+a+thalidomide-dependent+cereblon+substrate.">SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.</a> Nature Chemical Biology. 14 (10), 981-987 (2018).</li><li>Kronke, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lenalidomide+induces+ubiquitination+and+degradation+of+CK1alpha+in+del(5q)+MDS.">Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS.</a> Nature. 523 (7559), 183-188 (2015).</li><li>Sakamoto, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protacs:+chimeric+molecules+that+target+proteins+to+the+Skp1-Cullin-F+box+complex+for+ubiquitination+and+degradation.">Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.</a> Proceedings of the National Academy of Sciences of the United States of America. 98 (15), 8554-8559 (2001).</li><li>Sakamoto, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+Protacs+to+target+cancer-promoting+proteins+for+ubiquitination+and+degradation.">Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.</a> Molecular &amp; Cellular Proteomics. 2 (12), 1350-1358 (2003).</li><li>Schneekloth, J. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemical+genetic+control+of+protein+levels:+selective+in+vivo+targeted+degradation.">Chemical genetic control of protein levels: selective in vivo targeted degradation.</a> Journal of the American Chemical Society. 126 (12), 3748-3754 (2004).</li><li>Gu, S., Cui, D., Chen, X., Xiong, X., Zhao, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=PROTACs:+An+Emerging+Targeting+Technique+for+Protein+Degradation+in+Drug+Discovery.">PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.</a> Bioessays. 40 (4), e1700247 (2018).</li><li>Collins, I., Wang, H., Caldwell, J. J., Chopra, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemical+approaches+to+targeted+protein+degradation+through+modulation+of+the+ubiquitin-proteasome+pathway.">Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.</a> Biochemical Journal. 474 (7), 1127-1147 (2017).</li><li>Neklesa, T. K., Winkler, J. D., Crews, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeted+protein+degradation+by+PROTACs.">Targeted protein degradation by PROTACs.</a> Pharmacology &amp; Therapeutics. 174, 138-144 (2017).</li><li>Winter, G. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phthalimide+conjugation+as+a+strategy+for+in+vivo+target+protein+degradation.">Phthalimide conjugation as a strategy for in vivo target protein degradation.</a> Science. 348 (6241), 1376-1381 (2015).</li><li>Maniaci, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Homo-PROTACs:+bivalent+small-molecule+dimerizers+of+the+VHL+E3+ubiquitin+ligase+to+induce+self-degradation.">Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.</a> Nature Communications. 8 (1), 830 (2017).</li><li>Crew, A. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+and+Characterization+of+Von+Hippel-Lindau-Recruiting+Proteolysis+Targeting+Chimeras+(PROTACs)+of+TANK-Binding+Kinase+1.">Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.</a> Journal of Medicinal Chemistry. , (2017).</li><li>Lu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hijacking+the+E3+Ubiquitin+Ligase+Cereblon+to+Efficiently+Target+BRD4.">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.</a> Chemistry &amp; Biology. 22 (6), 755-763 (2015).</li><li>Steinebach, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=PROTAC-mediated+crosstalk+between+E3+ligases.">PROTAC-mediated crosstalk between E3 ligases.</a> Chemical Communications. 55 (12), 1821-1824 (2019).</li><li>Tinworth, C. P., Lithgow, H., Churcher, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Small+molecule-mediated+protein+knockdown+as+a+new+approach+to+drug+discovery.">Small molecule-mediated protein knockdown as a new approach to drug discovery.</a> Medchemcomm. 7 (12), 2206-2216 (2016).</li><li>Steinebach, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Homo-PROTACs+for+the+Chemical+Knockdown+of+Cereblon.">Homo-PROTACs for the Chemical Knockdown of Cereblon.</a> ACS Chemical Biology. 13 (9), 2771-2782 (2018).</li><li>Ambrozak, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synthesis+and+Antiangiogenic+Properties+of+Tetrafluorophthalimido+and+Tetrafluorobenzamido+Barbituric+Acids.">Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids.</a> ChemMedChem. 11 (23), 2621-2629 (2016).</li><li>Zhou, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Discovery+of+a+Small-Molecule+Degrader+of+Bromodomain+and+Extra-Terminal+(BET)+Proteins+with+Picomolar+Cellular+Potencies+and+Capable+of+Achieving+Tumor+Regression.">Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.</a> Journal of Medicinal Chemistry. , (2017).</li><li>Zhang, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Proteolysis+Targeting+Chimeras+(PROTACs)+of+Anaplastic+Lymphoma+Kinase+(ALK).">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).</a> European Journal of Medicinal Chemistry. 151, 304-314 (2018).</li><li>Runcie, A. C., Chan, K. H., Zengerle, M., Ciulli, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemical+genetics+approaches+for+selective+intervention+in+epigenetics.">Chemical genetics approaches for selective intervention in epigenetics.</a> Current Opinion in Chemical Biology. 33, 186-194 (2016).</li><li>Kronke, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lenalidomide+causes+selective+degradation+of+IKZF1+and+IKZF3+in+multiple+myeloma+cells.">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.</a> Science. 343 (6168), 301-305 (2014).</li><li>Eichner, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunomodulatory+drugs+disrupt+the+cereblon-CD147-MCT1+axis+to+exert+antitumor+activity+and+teratogenicity.">Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.</a> Nature Medicine. 22 (7), 735-743 (2016).</li><li>Zhu, Y. X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cereblon+expression+is+required+for+the+antimyeloma+activity+of+lenalidomide+and+pomalidomide.">Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.</a> Blood. 118 (18), 4771-4779 (2011).</li><li>Kortum, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeted+sequencing+of+refractory+myeloma+reveals+a+high+incidence+of+mutations+in+CRBN+and+Ras+pathway+genes.">Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.</a> Blood. 128 (9), 1226-1233 (2016).</li><li>Gil, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cereblon+deficiency+confers+resistance+against+polymicrobial+sepsis+by+the+activation+of+AMP+activated+protein+kinase+and+heme-oxygenase-1.">Cereblon deficiency confers resistance against polymicrobial sepsis by the activation of AMP activated protein kinase and heme-oxygenase-1.</a> Biochemical and Biophysical Research Communications. 495 (1), 976-981 (2018).</li><li>Kim, H. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cereblon+in+health+and+disease.">Cereblon in health and disease.</a> Pfl&#252;gers Archiv: European Journal of Physiology. 468 (8), 1299-1309 (2016).</li><li>Lee, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disruption+of+the+cereblon+gene+enhances+hepatic+AMPK+activity+and+prevents+high-fat+diet-induced+obesity+and+insulin+resistance+in+mice.">Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice.</a> Diabetes. 62 (6), 1855-1864 (2013).</li></ol>

The design of such homo-PROTACs as described here for CRBN relies on the specific affinity of pomalidomide to CRBN, which has been successfully utilized in numerous heterobifunctional PROTACs and resulted in the development of PROTAC 8 as a highly selective CRBN degrader. The specificity of our molecule has already been confirmed by proteomic analyses24. For genetically mediated knockout, exclusion and validation of side effects is challenging and time consuming. In addition, a ch...

The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all approved for the treatment of multiple myeloma, bind to the E3 ubiquitin ligase cereblon (CRBN), a substrate adaptor for cullin4A-RING E3 ubiquitin ligase (CRL4CRBN)1,2,3. Binding of IMiDs enhances the affinity of CRL4CRBN to the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to their ubiquitination and degradation (Figure 1)4,5,6,7,8. Since IKZF1 and IKZF3 are essential for multiple myeloma cells, their inactivation results in growth inhibition. SALL4 was recently found as an additional IMiD-induced neo-substrate of CRBN that is likely responsible for the teratogenicity and the so-called Contergan catastrophe in the 1950s caused by thalidomide9,10. In contrast, casein kinase 1&#945; (CK1&#945;) is a lenalidomide-specific substrate of CRBN that is implicated in the therapeutic effect in myelodysplastic syndrome with chromosome 5q deletions11.
The ability of small-molecules to target a specific protein for degradation is an exciting implication for modern drug development. While the mechanism of thalidomide and its analogs was discovered after their first use in humans, so called Proteolysis Targeting Chimeras (PROTACs) have been designed to specifically target a protein of interest (POI) (Figure 2)12,13,14,15,16,17,18. PROTACs are heterobifunctional molecules that consist of a specific ligand for the POI connected via a linker to a ligand of an E3 ubiquitin ligase like CRBN or von-Hippel-Lindau (VHL)18,19,20,21,22. PROTACs induce the formation of a transient ternary complex, directing the POI to the E3 ubiquitin ligase, resulting in its ubiquitination and proteasomal degradation. The major advantages of PROTACs over conventional inhibitors is that binding to a POI is sufficient rather than its inhibition and therefore PROTACs can potentially target a far wider spectrum of proteins including those that were considered to be undruggable like transcription factors15. In addition, chimeric molecules act catalytically and therefore have a high potency. After ubiquitin transfer to the POI, the ternary complex dissociates and is available for the formation of new complexes. Thus, very low PROTAC concentrations are sufficient for the degradation of the target protein23.
Here we describe the synthesis of a pomalidomide-pomalidomide conjugated homo-PROTAC (compound 8) that recruits CRBN for the degradation of itself24. The E3 ubiquitin ligase CRBN serves as both the recruiter and the target at the same time (Figure 3). To validate our data, we also synthesized a negative binding control (compound 9). Our data confirm that the newly synthesized homo-PROTAC is specific for CRBN degradation and has only minimal effects on other proteins.

<table>
	<tbody>
		<tr>
			<td>1,1&#39;-Carbonyldiimidazole</td>
			<td>TCI chemicals</td>
			<td>C0119</td>
			<td></td>
		</tr>
		<tr>
			<td>2,2&#8242;-(Ethylenedioxy)-bis(ethylamine)</td>
			<td>Sigma-Aldrich</td>
			<td>385506</td>
			<td>Compound 6</td>
		</tr>
		<tr>
			<td>2-Mercaptoethanol</td>
			<td>Sigma-Aldrich</td>
			<td>M6250</td>
			<td></td>
		</tr>
		<tr>
			<td>3-Fluorophthalic anhydride, 98 %</td>
			<td>Alfa Aesar</td>
			<td>A12275</td>
			<td></td>
		</tr>
		<tr>
			<td>4-Dimethylaminopyridine, 99 %</td>
			<td>Acros</td>
			<td>148270250</td>
			<td>Toxic</td>
		</tr>
		<tr>
			<td>Acrylamidstamml&#246;sung/ Bisacrylamid (30%/0,8%)</td>
			<td>Carl Roth</td>
			<td>3029.1</td>
			<td></td>
		</tr>
		<tr>
			<td>Aiolos (D1C1E) mAB</td>
			<td>Cell signaling</td>
			<td>15103S</td>
			<td></td>
		</tr>
		<tr>
			<td>Anti-CRBN antibody produced in rabbit</td>
			<td>Sigma</td>
			<td>HPA045910</td>
			<td></td>
		</tr>
		<tr>
			<td>Anti-rabbit IgG HRP-linked antibody</td>
			<td>Sigma</td>
			<td>7074S</td>
			<td></td>
		</tr>
		<tr>
			<td>Ammonium Persulfate</td>
			<td>Roth</td>
			<td>9592.2</td>
			<td></td>
		</tr>
		<tr>
			<td>Boc-Gln-OH</td>
			<td>TCI chemicals</td>
			<td>B1649</td>
			<td></td>
		</tr>
		<tr>
			<td>Bovine Serum Albumin</td>
			<td>Sigma-Aldrich</td>
			<td>A7906-100G</td>
			<td></td>
		</tr>
		<tr>
			<td>CellTiter-Glo Luminescent Cell Viability Assay</td>
			<td>Promega</td>
			<td>G7571</td>
			<td></td>
		</tr>
		<tr>
			<td>ChemiDoc XRS+</td>
			<td>Bio-Rad</td>
			<td>1708265</td>
			<td></td>
		</tr>
		<tr>
			<td>DMF, anhydrous, 99.8 %</td>
			<td>Acros</td>
			<td>348435000</td>
			<td>Extra Dry over Molecular Sieve</td>
		</tr>
		<tr>
			<td>DMSO, anhydrous, 99.7 %</td>
			<td>Acros</td>
			<td>348445000</td>
			<td>Extra Dry over Molecular Sieve</td>
		</tr>
		<tr>
			<td>Glycine</td>
			<td>Sigma-Aldrich</td>
			<td>15523-1L-R</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-mouse (HRP conjugated)</td>
			<td>Santa Cruz biotechnology</td>
			<td>sc-2005</td>
			<td></td>
		</tr>
		<tr>
			<td>Halt Protease &#38; Phosphatase Inhibitor Single-use Cocktail (100X)</td>
			<td>Thermo Scientific</td>
			<td>1861280</td>
			<td></td>
		</tr>
		<tr>
			<td>Ikaros (D6N9Y) Mab</td>
			<td>Cell signaling</td>
			<td>14859S</td>
			<td></td>
		</tr>
		<tr>
			<td>ImmobilonP Transfer Membrane (0,45&#181;m)</td>
			<td>Merck</td>
			<td>IPVH000010</td>
			<td></td>
		</tr>
		<tr>
			<td>Iodomethane, 99 %</td>
			<td>Sigma-Aldrich</td>
			<td>I8507</td>
			<td>Highly toxic</td>
		</tr>
		<tr>
			<td>Methanol</td>
			<td>Sigma-Aldrich</td>
			<td>32213-2.5L</td>
			<td></td>
		</tr>
		<tr>
			<td>Mg132</td>
			<td>Selleckchem</td>
			<td>S2619</td>
			<td></td>
		</tr>
		<tr>
			<td>Mini Trans-Blot electrophoretic transfer cell</td>
			<td>Bio-Rad</td>
			<td>1703930</td>
			<td></td>
		</tr>
		<tr>
			<td>Mini-PROTEAN Tetra Vertical Electrophoresis Cell</td>
			<td>Bio-Rad</td>
			<td>1658004</td>
			<td></td>
		</tr>
		<tr>
			<td>MLN4942</td>
			<td>biomol (cayman)</td>
			<td>Cay15217-1</td>
			<td></td>
		</tr>
		<tr>
			<td>Monoclonal Anti-&#945;-Tubulin antibody produced in mouse (B512)</td>
			<td>Sigma</td>
			<td>T5168</td>
			<td></td>
		</tr>
		<tr>
			<td>N-Ethyldiisopropylamine, 99 %</td>
			<td>Alfa Aesar</td>
			<td>A11801</td>
			<td></td>
		</tr>
		<tr>
			<td>Nonfat dried milk powder</td>
			<td>PanReac AppliChem</td>
			<td>A0830,0500</td>
			<td></td>
		</tr>
		<tr>
			<td>Nunc F96 MicroWell White Polystyrene Plate</td>
			<td>Thermo Scientific</td>
			<td>136101</td>
			<td></td>
		</tr>
		<tr>
			<td>NuPAGE LDS Sample Buffer (4X)</td>
			<td>Thermo Scientific</td>
			<td>NP0008</td>
			<td></td>
		</tr>
		<tr>
			<td>Pierce BCA Protein Assay kit</td>
			<td>Thermo Scientific</td>
			<td>23225</td>
			<td></td>
		</tr>
		<tr>
			<td>Pomalidomide</td>
			<td>Selleckchem</td>
			<td>S1567</td>
			<td></td>
		</tr>
		<tr>
			<td>RestoreTM Western Blot Stripping Buffer</td>
			<td>Thermo Scientific</td>
			<td>46430</td>
			<td></td>
		</tr>
		<tr>
			<td>sodium dodecyl sulfate</td>
			<td>Carl Roth</td>
			<td>183.1</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium Chloride</td>
			<td>Sigma-Aldrich</td>
			<td>A9539-500g</td>
			<td></td>
		</tr>
		<tr>
			<td>TEMED</td>
			<td>Carl Roth</td>
			<td>2367.3</td>
			<td></td>
		</tr>
		<tr>
			<td>tert-Butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate</td>
			<td>Sigma-Aldrich</td>
			<td>89761</td>
			<td>Compound 5</td>
		</tr>
		<tr>
			<td>Tricin</td>
			<td>Carl Roth</td>
			<td>6977.4</td>
			<td></td>
		</tr>
		<tr>
			<td>Trizma base</td>
			<td>Sigma-Aldrich</td>
			<td>T1503-1kg</td>
			<td></td>
		</tr>
		<tr>
			<td>Tween-20</td>
			<td>Sigma-Aldrich</td>
			<td>P7949-500ml</td>
			<td></td>
		</tr>
		<tr>
			<td>WesternBright ECL spray</td>
			<td>Advansta</td>
			<td>K-12049-D50</td>
			<td></td>
		</tr>
	</tbody>
</table>

chemical inactivation of the e3 ubiquitin ligase cereblon by pomalidomide-based homo-protacs

The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all FDA approved drugs for the treatment of multiple myeloma, induce ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase for proteasomal degradation. IMiDs have recently been utilized for the generation of bifunctional proteolysis targeting chimeras (PROTACs) to target other proteins for ubiquitination and proteasomal degradation by the CRBN E3 ligase. We designed and synthesized pomalidomide-based homobifunctional PROTACs and analyzed their ability to induce self-directed ubiquitination and degradation of CRBN. Here, CRBN serves as both, the E3 ubiquitin ligase and the target at the same time. The homo-PROTAC compound 8 degrades CRBN with a high potency with only minimal remaining effects on IKZF1 and IKZF3. CRBN inactivation by compound 8 had no effect on cell viability and proliferation of different multiple myeloma cell lines. This homo-PROTAC abrogates the effects of IMiDs in multiple myeloma cells. Therefore, our homodimeric pomalidomide-based compounds may help to identify CRBN&#8216;s endogenous substrates and physiological functions and investigate the molecular mechanism of IMiDs.

Here we described the design, synthesis and biological evaluation of a homodimeric pomalidomide-based PROTAC for the degradation of CRBN. Our PROTAC interacts simultaneously with two CRBN molecules and forms ternary complexes that induces self-ubiquitination and proteasomal degradation of CRBN with only minimal remaining effects on pomalidomide-induced neo-substrates IKZF1 or IKZF3.
Out of a series of previously published pomali...

Watch this Scientific Journal Video about Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs at JoVE.com

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

This work describes the synthesis and characterization of a pomalidomide-based, bifunctional homo-PROTAC as a novel approach to induce ubiquitination and degradation of the E3 ubiquitin ligase cereblon (CRBN), the target of thalidomide analogs.

The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all FDA approved drugs for the treatment of multiple ...

Our homodimeric PROTACs are the first chemical inhibitors of Cereblon and may help to further elucidate the molecular mechanism of thalidomide analogs, as well as to investigate the physiological function of Cereblon. This new PROTAC platform technology can be highly helpful for specifically targeting proteins of interest that are otherwise considered to be untrackable. CRBN inhibition alone has no anti-tumor activity.However, CRBN degraders may have clinical implications in obesity, infectious diseases, and other disorders. The synthesis is challenging and it's hard to find optimal linkers and attachment to generate effective protein degraders when designing a PROTAC compound. To begin, place 2.46 grams of Boc-protected L-glutamine and 50 milliliters of tetrahydrofuran in a 100 milliliter round-bottomed flask, and stir at 800 rpm for one minute.Then, add 1.95 grams of 1, 1'carbonyldiimidazole and a catalytic amount of 4-pyridine. Continue stirring for 10 hours at reflux to obtain a clear colorless solution of glutarimide compound. Let the solution cool to room temperature, and remove the solvent with a rotary evaporator.Redissolve the residue in 200 milliliters of ethyl acetate and pour it into a separatory funnel. Wash the organic layer with 50 milliliters each of deionized water and brine, and dry the organic layer over sodium sulfate. Gravity filter the solution through silica gel to remove the desiccant, and then rinse the silica gel with 200 milliliters of ethyl acetate.Remove the solvent from the filtrate under vacuum to obtain Compound 1 as a colorless solid. Dry the product under vacuum overnight before using it. Next, dissolve 0.50 grams of sodium acetate in 20 milliliters of glacial acetic acid in a 100 milliliter round-bottom flask equipped with a stir bar.Add 1.25 grams of 3-fluorophthalic anhydride and 1.14 grams of glutarimide and stir at reflux for six hours to obtain a purple solution of Compound 3. Let the mixture cool to room temperature, and then pour it into 100 milliliters of deionized water and stir for 10 minutes to precipitate Compound 3. Collect the solid by filtration, wash it with water and petroleum ether, and dry it under vacuum for two days.Next, place 0.83 grams of Compound Three and 20 milliliters of dry dimethyl sulfoxide in a 50 milliliter Schlenk flask and stir for two minutes. Add 0.22 grams of alpha omega diamine linker Compound 6, and 1.05 millilitres of N, N-diisopropylethylamine and stir the mixture under argon at 90 degrees celsius for 18 hours to obtain Homodimer 8 in a dark green mixture. Let the mixture cool to room temperature and pour it into 100 millilitres of deionized water.Extract the product into three 50 milliliter portions of ethyl acetate, combine the organic layers, and wash them with 50 milliliters each of water and brine. Dry the washed organic layer over sodium sulfate, filter out the desiccant and remove the solvent under vacuum. Redissolve the residue in a minimal amount of chromatography solvent and apply to a silica gel column for purification.Collect the fluorescent product fractions, combine them, and remove the solvent to obtain Homodimer 8 as a yellow solid. To begin, dissolve 2.28 grams of Glutarimide 1 in 25 milliliters of dimethylformamide in a 100 milliliter round-bottom flask. Suspend 2.76 grams of milled potassium carbonate in this solution.Then, draw 0.62 milliliters of iodomethane into a syringe equipped with a 20-gauge needle. Add the iodomethane drop-wise over the course of 10 seconds. Stopper the flask with a rubber septum, and add a vent needle.Sonicate the mixture for two hours at room temperature to obtain Glutarimide Compound 2. Dilute the mixture with 50 milliliters of ethyl acetate and pour it into a separatory funnel. Rinse the flask into the funnel with another 50 milliliters of ethyl acetate.Work up the product and purify it with silica gel column chromatography to obtain Glutarimide 2 as a colorless solid. Compare the retention times of Glutarimide Compounds 1 and 2 to confirm that N-methylation was successful. To begin the validation, treat multiple myeloma cells with the compounds of interest.Isolate the relevant proteins, and prepare samples for a Western Blot analysis of protein degradation. Then, prepare a gel sandwich for SDS-PAGE and fill the anode buffer tank with a pH 8.9 tris-HCl solution. Load the protein samples into the gel and run it at 70 Volts for 20 minutes, followed by 115 volts for 150 minutes.Next, prepare 1x transfer buffer for immunoblotting and carefully move the gel from its cassette to the transfer buffer to equilibrate. You have to be very careful when you remove the gel from the cassette for equilibration, because it can burst and crumple very quickly. Immerse a 0.45 micrometer polyvinylidene difluoride membrane in pure methanol for at least 20 seconds to activate it, and then immerse it in 1x transfer buffer.Let the gel and the membrane equilibrate for 10 minutes. Then, assemble the Western Blotting cassette and apply 180 milliamperes for 90 minutes to transfer the proteins to the membrane. Afterwards, visualize the proteins by immunostaining.To evaluate the effects on cell viability, first, seed 50, 000 multiple myeloma cells per well of a 96 well plate in biological triplicate. Add to each well 100 microliters of media containing DMSO, or a 0.1, one, or 10 micromolar of Compound 8, Compound 9, or pomalidomide. To perform cell viability rescue experiment, instead treat the cells with a 100 nanomolar solution of Compound 8 for three hours, either before or after adding a one micromolar solution of pomalidomide.Incubate the cells for 24, 48, or 96 hours at 37 degrees celsius in a 5%carbon dioxide atmosphere, and measure cell viability with a luminescent assay. The structure of homodimeric PROTAC 8 was confirmed with proton and carbon NMR. Heterodimeric PROTAC 9 was synthesized as a negative control, as N-methylation within the glutarimide portion results in a loss of Cereblon, or CRBN, binding capability.The homo PROTAC 8 induced near complete proteosomal CRBN degradation with minimal effects on the lymphoid transcription factors IKZF1 and IKZF3. In contrast, the hetero PROTAC 9 showed behavior similar to pomalidomides. Compound 8 induced CRBN degradation could be blocked by a direct inhibitor of the proteasome, or indirectly blocked by netylation inhibition.Cells pre-treated with Compound 8 significantly resisted the effects of pomalidomide on IKZF1 and IKZF3. Compound 8 induced CRBN degradation had much less of an effect on multiple myeloma cell viability after 96 hours than the IKZF1 and IKZF3 degradation from Compound 9 and pomalidomide did. Multiple myeloma cells pre-treated with Compound 8 had significantly greater viability when exposed to pomalidomide than untreated cells, suggesting that Compound 8 could be used to mimic immunomodulatory IMiD drug-resistance.We found that Compound 8 induces complete proteasomal degradation of Cereblon, has no side effects on IKZF1 and IKZF3 cell viability and proliferation. Extending the project technology to other targets has the potential for inactivating and tracking of proteins related to cancer and other diseases. When adapting this technique for other drugs and proteins, one should carefully investigate the molecular structures of the drug and the protein target to choose the optimal linkers and attachments.The IMiDs will not work in mice because of a point mutation in Cereblon, but a transgenic knock-in mouse model exists which can be used for further animal studies. As pomalidomide is an analog thalidomide, which is highly teratogenic, we do not recommend pregnant women working with these drugs.

Research

JoVE Journal

Chemistry

Origami Inspired Self-assembly of Patterned and Reconfigurable Particles

There are numerous techniques such as photolithography, electron-beam lithography and soft-lithography that can be used to precisely pattern two ...

Isolation and Chemical Characterization of Lipid A from Gram-negative Bacteria

Lipopolysaccharide (LPS) is the major cell surface molecule of gram-negative bacteria, deposited on the outer leaflet of the outer membrane bilayer. LPS ...

Preparing Adherent Cells for X-ray Fluorescence Imaging by Chemical Fixation

X-ray fluorescence imaging allows us to non-destructively measure the spatial distribution and concentration of multiple elements simultaneously over ...

Chemical Vapor Deposition of an Organic Magnet, Vanadium Tetracyanoethylene

Recent progress in the field of organic materials has yielded devices such as organic light emitting diodes (OLEDs) which have advantages not found in ...

Preparation of Highly Porous Coordination Polymer Coatings on Macroporous Polymer Monoliths for Enhanced Enrichment of Phosphopeptides

We describe a protocol for the preparation of hybrid materials based on highly porous coordination polymer coatings on the internal surface of macroporous ...

Preparation of Macroporous Epitaxial Quartz Films on Silicon by Chemical Solution Deposition

This work describes the detailed protocol for preparing piezoelectric macroporous epitaxial quartz films on silicon(100) substrates. This is a three-step ...

Epitaxial Growth of Perovskite Strontium Titanate on Germanium via Atomic Layer Deposition

Atomic layer deposition (ALD) is a commercially utilized deposition method for electronic materials. ALD growth of thin films offers thickness control and ...

Facile Synthesis of Worm-like Micelles by Visible Light Mediated Dispersion Polymerization Using Photoredox Catalyst

Presented herein is a protocol for the facile synthesis of worm-like micelles by visible light mediated dispersion polymerization. This approach begins ...